Simultaneously, the AMPK activator AICAR exhibited an effect comparable with CSF, while these effects induced by CSF were abolished by the AMPK inhibitor [29], which suggested that CSF might be a possible agent for hepatic steatosis therapy via targeting AMPK-dependent signal cascades. The gene discussed is PRKAA1; the disease is fatty liver disease.